President Donald Trump delivered a speech at the White House on December 17, reflecting on his accomplishments and initiatives during the first year of his second term in office. In his 18-minute address, Trump discussed a wide range of topics, including economic issues, military strength, and efforts to address illegal immigration.

One notable highlight was Trump’s mention of successful negotiations with pharmaceutical companies like Pfizer and AstraZeneca to lower drug prices in the U.S. to levels comparable to those in other countries, aiming to provide cost savings for American consumers.

During his speech, Trump made a mathematical error by suggesting a potential 600% reduction in drug prices, a figure that would imply pharmaceutical firms paying customers to use their products, which is logically impossible. Despite Trump’s claims of slashing drug prices by 400%, 500%, and 600%, the actual impact on consumers remains uncertain.

Reports indicate that the terms of agreements between the White House and pharmaceutical companies are confidential or still being finalized, leaving doubt about the direct benefits to consumers. Critics, including some on social media, seized on Trump’s mathematical misstep, questioning the feasibility of his proposed price cuts.

While some viewed Trump’s speech delivery as lacking finesse, others interpreted his intentions as aiming to eliminate excessive markups on drugs, potentially offering medications closer to cost prices. The discourse surrounding Trump’s statements continues to draw varied reactions and interpretations within the public sphere.